Results from the survey assessing willingness to receive a COVID vaccine; Dr. Fauci shares that he is ‘cautiously optimistic’ a vaccine could arrive before year’s end; And the breaking news that remdesivir (Veklury) has gained FDA approval.
This week: News of another vaccine trial being put on hold; A trial assessing hyperimmue globulin beings; An NDA for IV tramadol is rejected; FDA Committees vote on novel schizophrenia and bipolar I disorder therapy; And a first approval for Ebola.
So far, the therapies scheduled to be part of the trial are risankizumab, an interleukin-23 antagonist, and lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
This week: encouraging news on antibody therapies; EUA guidelines for potential vaccines; Remdesivir distribution; The HIV drug that failed to have an impact; And the preterm birth treatment the FDA want withdrawn from the market.
This week we cover new Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok ‘challenge’; And FDA grants Nucala new approval. Also we look at this week’s developments in drugs in the pipeline.
Genexa has launched 4 over-the-counter (OTC) medicines that contain no artificial ingredients.
This week we cover AstraZeneca and the swift decision to restart their COVID-19 vaccine candidate trial; Pfizer and BioNTech want to expand enrollment for their candidate vaccine trial; There’s the Janus kinase inhibitor that could help reduce recovery time; An investigative antiviral may ease strain on hospitalizations; Aortic aneurysm, dissection assessed with fluoroquinolones; And a retrospective study compared cardiac events with azithromycin and amoxicillin use.
We cover AstraZeneca’s decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we wrap up the latest news on drugs in the pipeline.
The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there’s developments in convalescent plasma authorization, a 15 minute test, and ethnobotanist’s give a stark warning concerning a plant that some are touting as a cure. In other news an intrauterine device gains expanded approval and there’s a label update for hydrochlorothiazide.
Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it’s shelf life extended. Also, we recap drug pipeline news from the past week.
